Loading stock data…
CPRX
$31.34+0.06 (+0.19%)
After Hours$31.17-0.17 (-0.54%)· Last close Jun 9
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Catalyst Pharmaceuticals, Inc. in the Healthcare sector is trading at $31.34. Wall Street consensus targets $32.60 (5 analysts), implying a +4.0% move over the next 12 months. The stock is currently near its 52-week high of $32.56, remaining 30.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$31.34
Potential Downside
0%
Whystock Fair Value$31.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Hold
Mean target$32.60+4.0%
Range$31.50 – $36.00
Fundamentals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.85%
Volume
Today's trading volume
1.31M
Recent News
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide.
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story
Angelini Pharma has entered a definitive agreement to acquire Catalyst Pharmaceuticals (NasdaqCM:CPRX). The deal marks Angelini Pharma's planned entry into the U.S. market focused on brain health and rare diseases. At the same time, all outstanding patent litigation related to FIRDAPSE is being resolved. The transaction and litigation settlement are expected to reshape Catalyst's future operations and legal profile. Catalyst Pharmaceuticals focuses on treatments for rare neurological...
CPRX or UTHR: Which Is the Better Value Stock Right Now?
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.